Q-omics provides the consensus-scored MRPS28 profile across patient tissues and cancer cell-line models. MRPS28 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MRPS28 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, MRPS28 protein abundance shows 19,401 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, KIRC, and LSCC as cancer lineages where MRPS28 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRPS28 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRPS28 survival associations across molecular data types. MRPS28 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRPS28 RNA expression–survival associations across cancer types. High MRPS28 expression shows unfavorable associations in UVM, HNSC, CESC and SCLC, but favorable associations in LGG and KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MRPS28 RNA expression.
This table summarizes MRPS28 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MRPS28. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRPS28 shows lower tumor expression in KIRC and THCA and higher tumor expression in HNSC, LIHC, STAD and BRCA. The KIRC box plot shows higher MRPS28 RNA expression in normal versus tumor tissue (log2 FC = −0.512, t-test p < 0.001).
This table shows molecular features associated with MRPS28 in patient tissues and cancer cell lines. In patient samples, MRPS28 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MRPS28 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and UPPER_AERODIGESTIVE_TRACT.
